Photo detail

Stories this photo appears in:

Neurocrine Reports Q1 Results

Neurocrine Biosciences Inc. has swelled its balance sheet in the first quarter of 2014.

Tease photo

Neurocrine Stock Increases As Drug Shows Promising Results

Stock for San Diego’s Neurocrine Biosciences Inc. nearly doubled its value after it released positive interim clinical data for its drug that treats tardive dyskinesia, a movement disorder that causes facial spasms.

Tease photo